Vapotherm Blog

CAUTION: US Federal law restricts this device to sale by or on the order of a physician. Indications, contraindications, warnings, and instructions for use can be found in the product labelling supplied with each device or at For spontaneously breathing patients. High Velocity Therapy (HVT) does not provide total ventilatory requirements of the patient. It is not a ventilator. Decisions surrounding patient care depend on the physician’s professional judgment in consideration of all available information for the individual case, including escalation of care depending on patient condition. 

Vapotherm provides high velocity nasal insufflation (HVNI) with simultaneous oxygen delivery to augment breathing of spontaneously breathing patients suffering from respiratory distress and/or hypoxemia in the hospital setting. It is not intended to provide total ventilatory requirements of the patient and not for use during field transport. 
The information provided in this section is for educational purposes only. This information is not intended to support the safety or effectiveness of Vapotherm products, or diagnose, treat, cure, or prevent any disease. It is not a substitute for consultation with your healthcare provider and should not be construed as medical advice. 

Patient in a hospital bed

What is the difference between Respiratory Care Department Billing Systems vs Productivity Systems?

Billing and Productivity systems are the backbone allowing Respiratory Departments to demonstrate their financial value and efficiency in performing services. Too often though, they get conflated, where a Billing system serves as the proxy for Productivity — something that should not happen.

Open Book

How to Make Sense of Charting, Charging, Costing, Reimbursement, and Productivity—Fundamentals for Respiratory Therapists in Inpatient Settings

For many of us during our respiratory care training, we were taught to focus on clinical documentation, which remains the focus for the bedside Respiratory Therapist (RT).

Image of a zoom conversation between Respratory Department directors

Velocity – Ep 8 – Respiratory Directors Share COVID-19 Experiences

Respiratory Department leaders Shelly Brown from Arkansas, Vernon Druses from New York, and Lenny Nyangwara from Maryland, continue their COVID-19 conversation from our last episode. Here they touch on relevant issues such as how they’ve dealt with supply shortages including PPE, and what COVID-19 advice they would give to colleagues who have not yet been hit hard by the pandemic.

Patient wearing the FELIX-1

[FELIX-1 White Paper] – Computational Fluid Dynamic Modelling of Particle Capture: Possible Use of a Modified Face-Tent as a Facial Scavenger

Aerosol generating procedures (AGPs) present a substantial clinical challenge during any clinical interaction, much less during a global viral pandemic. Control of AGPs during respiratory therapy procedures is important. Various methods of mitigation have been proposed for non-invasive ventilatory support.

Patient wearing the FELIX-1

FELIX-1: Creating a Localized Area of Negative Pressure for COVID-19 Patients

Even before COVID-19 became a truly global pandemic, it became clear that protecting healthcare workers (HCWs) from infection was crucial. Many major health organizations, like the Centers for Disease Control and Prevention (CDC), the World Health Organization (WHO).

Image of a zoom conversation between Respratory Department directors

Velocity – Ep 7 – Respiratory Directors Share COVID-19 Experiences

Shelly Brown from Arkansas, Vernon Druses from New York, and Lenny Nyangwara from Maryland are all Respiratory Department leaders.
They share their experiences on how the coronavirus pandemic has impacted their hospitals and clinical practice and discuss treating the respiratory symptoms associated with COVID-19.

Image of a zoom conversation between Respratory Department directors

Velocity – Ep 6 – An ED Physician and COVID-19 Patient (Part 2)

Dr. Louis Philip Rotkowitz is an ER doctor out of Queens, NYC. Like so many other health care professionals, he would find himself fighting COVID-19 as a patient. In this episode, Dr. Rotkowitz reflects on his experience in a conversation with fellow ER physician, Dr. Kirk Hinkley.

Image of Vapotherm CEO Joe Army and Vapotherm Sr. Manufacturing Manager Jay Dow in the Vapotherm Clean Room wearing masks, gowns, and hair covers

We’re here for you. A COVID-19 update from CEO Joe Army

The pandemic isn’t over. Vapotherm CEO Joe Army brings you to our Exeter, NH headquarters to share what we’ve been up to to best support you and your patients.

Image of a patient. A Vapotherm Precision Flow unit is visible in the background.

Thinking Outside the Mask with COPD

Clinicians familiar with literature on Vapotherm high velocity therapy are already aware that Vapotherm therapy has been clinically proven to be comparable to noninvasive positive pressure ventilation (NiPPV) when treating respiratory distress in spontaneously breathing patients. In a 2018 randomized, controlled, multi-center noninferiority trial, Doshi and colleagues compared the efficacy of a mask-free form of NIV (Vapotherm high velocity therapy) to an established respiratory support modality (NiPPV).

Image of female patient with a Vapotherm cannula. A Vapotherm Precision Flow unit is being adjusted in the background.

New Analysis Suggests Vapotherm High Velocity Therapy May Be as Effective as Noninvasive Positive Pressure Ventilation (NiPPV) Among Studied Hypercapnic Patients

In April 2020, Doshi and colleagues published the results of a subgroup analysis in Heart & Lung titled “The ventilatory effect of high velocity nasal insufflation compared to non-invasive positive-pressure ventilation in the treatment of hypercapneic respiratory failure: a subgroup analysis.” The analyses examined the hypercapnic sub-population of a multi-center, randomized, controlled, non-inferiority trial.